5.25

1.69% -0.09

After Hours: 5.30 0.05 +0.95%

Alector Inc (ALEC)

Overview News Price History Option Chain Discussions Forecast

Alector Inc stock is currently priced at $5.25, with a 24-hour trading volume of 360.27K. It has seen a -1.69% decreased in the last 24 hours and a -12.21% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $5.31 pivot point. If it approaches the $5.22 support level, significant changes may occur.

Previous Close:

$5.34

Open:

$5.34

24h Volume:

360.27K

Market Cap:

$502.68M

Revenue:

$97.06M

Net Income/Loss:

$-130.39M

P/E Ratio:

-3.0523

EPS:

-1.72

Net Cash Flow:

$-186.54M

1W Performance:

+3.55%

1M Performance:

-12.21%

6M Performance:

-0.57%

1Y Performance:

-18.60%

1D Range:

$5.21

$5.37

52W Range:

$3.66

$9.065

Alector Inc Stock (ALEC) Company Profile

Name

Alector Inc

Sector

Healthcare (1200)

Industry

Biotechnology (688)

Phone

415-231-5660

Address

151 Oyster Point Boulevard, Suite 300, South San Francisco

Employee

Twitter

Next Earnings Date

2024-05-02

Latest SEC Filings

ALEC's Discussions on Twitter

Alector Inc Stock (ALEC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-07-22	Initiated	Mizuho	Buy
Apr-13-22	Initiated	Goldman	Sell
Mar-08-22	Downgrade	Stifel	Buy → Hold
Sep-27-21	Initiated	William Blair	Outperform
Jan-15-21	Resumed	BofA Securities	Buy
Jun-24-20	Initiated	H.C. Wainwright	Buy
Apr-28-20	Initiated	Goldman	Buy
Mar-06-20	Initiated	Citigroup	Buy
Feb-27-20	Initiated	Barclays	Overweight
Feb-19-20	Initiated	Stifel	Buy
Nov-21-19	Initiated	BTIG Research	Buy
Mar-04-19	Initiated	Barclays	Overweight
Mar-04-19	Initiated	BofA/Merrill	Buy
Mar-04-19	Initiated	Morgan Stanley	Overweight
Mar-04-19	Initiated	SVB Leerink	Outperform

View All

Alector Inc Stock (ALEC) Latest News

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease

GlobeNewswire Inc.

Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?

Zacks Investment Research

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

GlobeNewswire Inc.

Alector Inc Stock (ALEC) Financials Data

Alector Inc (ALEC) Revenue 2024

ALEC reported a revenue (TTM) of $97.06 million for the quarter ending December 31, 2023, a -27.36% decline year-over-year.

Alector Inc (ALEC) Net Income 2024

ALEC net income (TTM) was -$130.39 million for the quarter ending December 31, 2023, a +2.19% increase year-over-year.

Alector Inc (ALEC) Cash Flow 2024

ALEC recorded a free cash flow (TTM) of -$186.54 million for the quarter ending December 31, 2023, a -663.08% decrease year-over-year.

Alector Inc (ALEC) Earnings per Share 2024

ALEC earnings per share (TTM) was -$1.55 for the quarter ending December 31, 2023, a +3.73% growth year-over-year.

Alector Inc Stock (ALEC) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Kenkare-Mitra Sara	President and Head of R&D	Mar 04 '24	Sale	6.92	10,169	70,387	318,847
Romano Gary	Chief Medical Officer	Mar 04 '24	Sale	6.92	6,001	41,554	196,313
GRASSO MARC	Chief Financial Officer	Mar 04 '24	Sale	6.92	5,716	39,562	144,957
Rosenthal Arnon	Chief Executive Officer	Dec 04 '23	Sale	5.56	23,831	132,500	2,019,217
Kenkare-Mitra Sara	President and Head of R&D	Dec 04 '23	Sale	5.56	12,519	69,606	329,016
Romano Gary	Chief Medical Officer	Dec 04 '23	Sale	5.56	5,035	27,995	202,314
GRASSO MARC	Chief Financial Officer	Dec 04 '23	Sale	5.56	4,574	25,431	150,673
Polaris Venture Management Co.	10% Owner	Sep 11 '23	Sale	6.00	500,000	3,000,000	10,853,817
MCGUIRE TERRANCE	Director	Sep 11 '23	Sale	6.00	500,000	3,000,000	10,853,817
Kenkare-Mitra Sara	President and Head of R&D	Sep 05 '23	Sale	5.19	6,214	32,277	177,935

Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of Alzheimer's and Parkinson's diseases; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under preclinical research stage. The company was founded in 2013 and is headquartered in South San Francisco, California.